Nephroscreen. A robust and versatile renal tubule-on-a-chip platform for nephrotoxicity assessment

dc.accessRightsAnonymous*
dc.contributor.authorSuter-Dick, Laura
dc.contributor.authorVriend, Jelle
dc.contributor.authorVormann, Marianne
dc.contributor.authorLanz, Henriette
dc.contributor.authorJoore, Jos
dc.contributor.authorTrietsch, Sebastian J.
dc.contributor.authorRussel, Frans
dc.contributor.authorJacobsen, Björn
dc.contributor.authorRoth, Adrian
dc.contributor.authorLu, Shuyan
dc.contributor.authorPolli, Joseph
dc.contributor.authorNaidoo, Anita
dc.contributor.authorMasereeuw, Rosalinde
dc.contributor.authorWilmer, Martijn
dc.date.accessioned2022-02-22T13:22:32Z
dc.date.available2022-02-22T13:22:32Z
dc.date.issued2021-03
dc.description.abstractProximal tubule epithelial cells are the main driver of renal transport and secretion of xenobiotics, making them susceptible to drug-induced kidney injury. Cell-based assays are a meaningful alternative to animal testing to detect nephrotoxicity and contribute to the 3Rs (refine, reduce, replace animal experimentation). Here we report on a high-throughput, three-dimensional microfluidic platform (Nephroscreen) to detect drug-induced nephrotoxicity. Toxicologically relevant parameters were used to assess cell viability, functional epithelial barrier integrity, and interactions with specific transporters (P-glycoprotein: P-gp and multidrug resistance–associated protein 2/4: MRP2/4). Nephroscreen allowed the combination of a variety of read-outs, including imaging, extracellularly released markers, intracellular markers, and functional assays. Nephroscreen is compatible with automated pipetting, proved to be amenable to long-term experiments (at least 11 days), and was easily transferred between laboratories. The compelling data originate from several published reports on the development and implementation of this platform to detect nephrotoxicity and drug–transporter interactions. The reports demonstrate that Nephroscreen could be used to detect the nephrotoxic liabilities of the tested compounds. Future directions should include additional test compounds and thorough validation of its performance.en_US
dc.identifier.doi10.1016/j.cotox.2021.03.001
dc.identifier.issn2468-2934
dc.identifier.issn2468-2020
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/33322
dc.identifier.urihttps://doi.org/10.26041/fhnw-4112
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.ispartofCurrent Opinion in Toxicologyen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/en_US
dc.subjectRenal proximal tubuleen_US
dc.subjectNephrotoxicityen_US
dc.subjectDrug screeningen_US
dc.subjectDrug–transporter interactionen_US
dc.subjectmiRNA Kidney-on-a-Chipen_US
dc.subjectMicrofluidicsen_US
dc.titleNephroscreen. A robust and versatile renal tubule-on-a-chip platform for nephrotoxicity assessmenten_US
dc.type01A - Beitrag in wissenschaftlicher Zeitschrift
dc.volume25en_US
dspace.entity.typePublication
fhnw.InventedHereYesen_US
fhnw.IsStudentsWorknoen_US
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publicationen_US
fhnw.affiliation.hochschuleHochschule für Life Sciences FHNWde_CH
fhnw.affiliation.institutInstitut für Chemie und Bioanalytikde_CH
fhnw.openAccessCategoryHybriden_US
fhnw.pagination42-48en_US
fhnw.publicationStatePublisheden_US
relation.isAuthorOfPublication37292405-e311-4093-a2e7-9a72a2511114
relation.isAuthorOfPublication.latestForDiscovery37292405-e311-4093-a2e7-9a72a2511114
Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild
Name:
1-s2.0-S246820202100005X-main.pdf
Größe:
797.65 KB
Format:
Adobe Portable Document Format
Beschreibung: